The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Chemoradiation And Adjuvant Chemotherapy Versus Radiation Alone In High Risk And Advanced Endometrial Cancer
Funder
National Health and Medical Research Council
Funding Amount
$460,832.00
Summary
This trial is evaluating whether adding chemotherapy during and after radiotherapy is better than giving radiotherapy alone in patients who have advanced or high risk endometrial cancer. One group of patients will be treated after surgery with both radiotherapy and chemotherapy, followed by additional cycles of chemotherapy and the other group will receive the standard treatment which is pelvic radiation alone. This study may result in a change in the management of these patients.
Genetic And Epigenetic Mechanisms Determining Responses To Therapies In Non-small Cell Lung Cancer
Funder
National Health and Medical Research Council
Funding Amount
$22,677.00
Summary
Lung cancer results in more cancer related deaths than any other cancer. The aim of this study is to identify prognostic and predictive markers for patients with non-small cell lung cancer (NSCLC) treated with chemotherapy, palliative radiotherapy and also novel targeted agents. This will help to better utilise these treatments and hopefully improve outcomes in patients with NSCLC.
Randomised Trials Of Adjuvant Cytotoxic & Endocrine Therapy For Early N+ And N- Breast Cancer
Funder
National Health and Medical Research Council
Funding Amount
$510,509.00
Summary
This application covers 4 adjuvant early breast cancer trials currently part of the Australian New Zealand Breast Cancer Trials Group's national research programme. These trials are international collaborations involving the International Breast Cancer Study Group (IBCSG). Two of the studies concern pre, peri and post-menopausal women with early breast cancer and no involved lymph glands (IBCSG 8 and 9), and two concern pre, peri and post-menopausal women with early breast cancer and involved ly ....This application covers 4 adjuvant early breast cancer trials currently part of the Australian New Zealand Breast Cancer Trials Group's national research programme. These trials are international collaborations involving the International Breast Cancer Study Group (IBCSG). Two of the studies concern pre, peri and post-menopausal women with early breast cancer and no involved lymph glands (IBCSG 8 and 9), and two concern pre, peri and post-menopausal women with early breast cancer and involved lymph glands (IBCSG 13 and 14). In the absence of a definitive cure, the largest gains will come from optimal use of current therapies and new therapies to improve survival, and where possible, to reduce morbidity without the loss of efficacy. These four trials can realistically expect to produce important gains with potential benefit to the many women who are diagnosed with early breast cancer each year. The active accrual period for these studies is complete but all patients are currently on life long follow-up. Patients accrued to trial 8 have a clinical assessment 3 monthly to 2 years, 6 monthly to 5 years, and then annually. For trials 9, 13 and 14 women have a clinical assessment 3 monthly during year 1, 6 monthly for year 2 and then annually.Read moreRead less
Identification Of Biomarkers Of Response And Toxicity To Chemoradiotherapy For Oesophageal Tumours
Funder
National Health and Medical Research Council
Funding Amount
$496,935.00
Summary
Chemoradiotherapy for oesophageal tumours has high interpatient variability in response and toxicity to treatment. Predictive biomarkers of response and toxicity would help select patients who would benefit most from this treatment modality. The proposed project will determine blood-derived microRNA and mRNA profiles that identify patients according to risk of unfavourable treatment outcomes, enabling clinicians to offer personalised alternative treatment strategies for those patients.
Utilising Circulating Tumour DNA (ctDNA) To Optimise The Adjuvant Therapy And Follow-up Of Patients With Locally Advanced Rectal Cancer
Funder
National Health and Medical Research Council
Funding Amount
$1,316,682.00
Summary
The management of patients after surgery for rectal cancer presents multilpe dilemmas; what treatment should be given and to which patients? Our initial studies in colorectal cancer patients demonstrate that a novel blood biomarker (circulating tumour DNA) can accurately predict patient risk of recurrence and with serial samples, can indicate whether chemotherapy is being effective. During follow-up changes in this biomarker promise to be a specific and very early indicator of cancer recurrence.
Engineered Spiky Silica Nanoparticles As Effective Immune Adjuvants By Activating Inflammasome And Enhancing Cellular Uptake
Funder
National Health and Medical Research Council
Funding Amount
$318,768.00
Summary
Vaccination is a triumph of preventative healthcare in Australia and worldwide. Despite substantial advances in vaccine development, some of the most lethal diseases still lack effective vaccines. This project aims to generate a novel immune adjuvant with excellent safety to promote antigen immunity by rationally designing surface structure of nanomaterials. Successful completing of this project has great potential to bring new, safe and potent vaccines for some infectious disease and cancer.